Partner Therapeutics is developing therapeutics for cancer and other serious diseases like COVID-19. Partner takes an innovative approach to therapeutic design by focusing on collaboration and partnership with leading companies, research centers and investigators to ensure products are rigorously tested. Partnering enables faster progress of treatment development programs to get effective therapies to patients sooner. Partner’s lead therapy is LEUKINE, the first and only FDA-approved granulocyte-macrophage colony-stimulating factor (GM-CSF). LEUKINE activates a multilineage immune defense against infection and has shown promising results in a Phase 3 clinical trial. Partner is also evaluating the efficacy of LEUKINE in patients with COVID-19 associated respiratory illness.